Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 20/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 20/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 20/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4729593 | 1.00 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL4729915 | 0.99 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL4729535 | 0.94 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL4730088 | 0.89 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL28067236 | 0.88 | HDAC3 (0.79) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL16677851 | 0.88 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL18742647 | 0.86 | HDAC3 (0.78) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL18822437 | 0.86 | HDAC3 (0.89) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL16677938 | 0.86 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL8739601 | 0.86 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20260108514-A1 | METHOD OF INHIBITING EPITHELIAL-MESENCHYMAL TRANSITION AND CANCER METASTASIS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2026-04-23 | — | — | US | claimed |
| EP-4601630-A1 | SELECTIVE HYPOTHALAMUS PERMEABLE HDAC6 INHIBITORS FOR TREATMENT OF LEPTIN-RESISTANT OBESITY | The Children's Medical Center Corporation (US) | 2025-08-20 | — | — | EP | claimed |
| US-20250213561-A1 | SELECTIVE HYPOTHALAMUS PERMEABLE HDAC6 INHIBITORS FOR TREATMENT OF LEPTIN-RESISTANT OBESITY | THE GENERAL HOSPITAL CORPORATION | 2025-07-03 | — | — | US | claimed |
| WO-2025085598-A2 | PERSONALIZED REGENERATIVE CELLS | IMMORTA BIO, INC. (US) | 2025-04-24 | — | — | WO | claimed |
| US-20250115871-A1 | METHODS TO IMPROVE ENDURING HEMATOPOIETIC STEM CELL TRANSPLANTATION | TRAILHEAD BIOSYSTEMS INC. | 2025-04-10 | — | — | US | claimed |
| WO-2025059442-A1 | MODULATING PLANT RESPONSES TO STRESS AND GROWTH WITH CHEMICALS | REMOTE EPIGENETICS INC. (US) | 2025-03-20 | — | — | WO | claimed |
| EP-4441205-A1 | METHODS AND COMPOSITIONS FOR MAINTAINING AND EXPANDING HEMATOPOIETIC STEM CELLS | Trailhead Biosystems Inc. (US) | 2024-10-09 | — | — | EP | claimed |
| EP-4410284-A1 | COMPOUND AND METHOD FOR THE TREATMENT OF ZELLWEGER SPECTRUM DISORDER | Apteeus (FR) | 2024-08-07 | — | — | EP | claimed |
| US-20240252496-A1 | SELECTIVE HYPOTHALAMUS PERMEABLE HDAC6 INHIBITORS FORTREATMENT OF LEPTIN-RESISTANT OBESITY | THE GENERAL HOSPITAL CORPORATION | 2024-08-01 | — | — | US | claimed |
| US-20240139187-A1 | SELECTIVE HYPOTHALAMUS PERMEABLE HDAC6 INHIBITORS FOR TREATMENT OF LEPTIN-RESISTANT OBESITY | THE GENERAL HOSPITAL CORPORATION | 2024-05-02 | — | — | US | claimed |
| WO-2024081587-A1 | SELECTIVE HYPOTHALAMUS PERMEABLE HDAC6 INHIBITORS FOR TREATMENT OF LEPTIN-RESISTANT OBESITY | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-04-18 | — | — | WO | claimed |
| US-20230391868-A1 | COMPOSITIONS FOR AND METHODS OF TREATING CANCER | THE GEORGE WASHINGTON UNIVERSITY | 2023-12-07 | — | — | US | claimed |
| CN-116510024-A | Composition, preparation method and application thereof | 上海复东生物医药有限责任公司 | 2023-08-01 | — | — | CN | claimed |
| WO-2023101943-A1 | METHODS AND COMPOSITIONS FOR MAINTAINING AND EXPANDING HEMATOPOIETIC STEM CELLS | TRAILHEAD BIOSYSTEMS INC. (US) | 2023-06-08 | — | — | WO | claimed |
| CN-115192714-A | Application of HDAC6 inhibitor in preparation of medicine for treating DNMT3A gene deletion cancer | 沈阳药科大学 | 2022-10-18 | — | — | CN | claimed |
| CN-114908049-A | Use of HDAC6 inhibitors to selectively induce T cell expansion | 江苏集萃医学免疫技术研究所有限公司 | 2022-08-16 | — | — | CN | claimed |
| CN-108752435-B | Acetylated hepatitis E virus capsid protein ORF2 and uses thereof | 中国食品药品检定研究院 | 2022-07-15 | — | — | CN | claimed |
| CN-108795882-B | Methods for modulating hepatitis E virus assembly and stability of capsid protein ORF2 | 中国食品药品检定研究院 | 2022-07-08 | — | — | CN | claimed |
| US-20220184075-A1 | PHARMACEUTICAL COMPOSITION CONTAINING HDAC6 INHIBITOR AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF ITCHING | BNH RES CO LTD (KR) | 2022-06-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213561-A1 | SELECTIVE HYPOTHALAMUS PERMEABLE HDAC6 INHIBITORS FOR TREATMENT OF LEPTIN-RESISTANT OBESITY | HDAC6, HDAC3, HDAC1 | HDAC3 2/4885HDAC1 3/4885HDAC2 5/4885 |
| US-20260108514-A1 | METHOD OF INHIBITING EPITHELIAL-MESENCHYMAL TRANSITION AND CANCER METASTASIS | HDAC5, HDAC6, GSK3B | HDAC3 4/4885HDAC1 5/4885HDAC2 18/4885 |
| US-20240252496-A1 | SELECTIVE HYPOTHALAMUS PERMEABLE HDAC6 INHIBITORS FORTREATMENT OF LEPTIN-RESISTANT OBESITY | HDAC6, HDAC3, HDAC1 | HDAC3 2/4885HDAC1 3/4885HDAC2 5/4885 |
| US-20230391868-A1 | COMPOSITIONS FOR AND METHODS OF TREATING CANCER | CD47, HDAC6, HDAC3 | HDAC3 3/4885HDAC1 4/4885HDAC2 11/4885 |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | WNT3A, GSK3B, GSK3A | HDAC3 97/4885HDAC1 71/4885HDAC2 432/4885 |
| US-20240139187-A1 | SELECTIVE HYPOTHALAMUS PERMEABLE HDAC6 INHIBITORS FOR TREATMENT OF LEPTIN-RESISTANT OBESITY | HDAC6, HDAC3, HDAC1 | HDAC3 2/4885HDAC1 3/4885HDAC2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.